<section class="ondra-article-page">
<div class="ondra-article-hero"> <div class="ondra-article-container"> <div class="ondra-article-meta-row"> <span class="ondra-meta-pill">⏱ 10 min read</span> <span class="ondra-meta-pill">🏷 Cost</span> </div> <h1 class="ondra-article-title">GLP-1 Medication Cost Comparison: Compounded, Direct-Pay, and Brand-Name</h1> <p class="ondra-article-intro">The price of a GLP-1 medication depends almost entirely on how you access it — not on the molecule itself. The same active ingredient (semaglutide or tirzepatide) is available at prices ranging from roughly $113 to $1,349 per month depending on the supply channel. This guide explains every option clearly, with honest numbers and no hidden agenda about which one you should choose.</p> </div>
</div> <div class="ondra-article-container ondra-article-body"> <div class="ondra-article-layout" id="ondraArticleLayout"> <div class="ondra-article-main" id="ondraArticleMain"> <a href="/blog" class="ondra-back-link">← Back to all articles</a> <div class="ondra-takeaways-card"> <h2 class="ondra-card-heading">Key takeaways</h2> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>There are three main supply channels: compounded telehealth (roughly $113–$479/month), manufacturer direct-pay programs (roughly $149–$699/month), and retail brand-name (roughly $900–$1,349/month without insurance).</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Compounded medications are not FDA-approved. Clinical trial efficacy data (STEP 1, SURMOUNT-1) applies only to FDA-approved brand-name products.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>For many cash-pay patients without GLP-1 insurance coverage, compounded telehealth is the lowest-cost path. Manufacturer direct-pay programs are a middle option for those who want FDA-approved medication at reduced (but still higher) cost.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Insurance coverage for GLP-1 medications for weight management remains inconsistent — many plans still exclude or limit this indication.</p> </div> </div> <div class="ondra-section"> <h2>Why GLP-1 prices vary so much</h2> <p>Semaglutide is semaglutide. Tirzepatide is tirzepatide. The active molecule in a $113/month compounded vial and a roughly $1,349/month brand-name pen is, at the molecular level, the same thing. The price difference reflects regulatory pathway, manufacturing overhead, clinical development cost recovery, marketing spend, and platform economics — not molecular differences. (This is a statement about the active ingredient, not about equivalence of the finished product; compounded and FDA-approved products differ in ways described throughout this article.)</p> <p>Per the <a href="https://www.cdc.gov/obesity/adult-obesity-facts/index.html" target="_blank" rel="noopener noreferrer">Centers for Disease Control and Prevention</a> (CDC, NHANES 2017–March 2020), 41.9% of US adults have obesity — the primary population for whom GLP-1 weight management treatment was developed. The scale of demand has created a tiered market with a large price spread for the same therapeutic class.</p> <p>Understanding which channel is right for you requires understanding what you are actually buying at each price point.</p> </div> <div class="ondra-section"> <h2>Channel 1: Compounded telehealth (roughly $113–$479/month)</h2> <p>Compounded GLP-1 medications are prepared by state-licensed compounding pharmacies to individual patient prescriptions issued by telehealth providers. The active ingredient is the same as in brand-name products, but the finished medication is not FDA-approved — it has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality.</p> <p>Per the <a href="https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers" target="_blank" rel="noopener noreferrer">FDA's guidance on compounding</a>, compounded drugs are not FDA-approved, which means the FDA does not review these drugs for safety, effectiveness, or quality before they are marketed. This is the fundamental regulatory distinction between compounded and brand-name products, and it is worth understanding clearly before choosing this path.</p> <div class="ondra-info-card"> <p class="ondra-info-title">Compounded telehealth pricing</p> <p><strong>Ondra Health:</strong> Compounded semaglutide from $113/month (quarterly plan); compounded tirzepatide from $183/month (quarterly plan). Flat pricing — same cost at all dose levels. Named pharmacy partners. LegitScript certified. No membership fee.<br/><br/><strong>Retail brand-name comparison reference:</strong> Wegovy® retails at approximately $1,349/month and Zepbound® at approximately $1,086/month without insurance; these figures move over time, so verify current pricing. These are the FDA-approved equivalents — not available through Ondra, but included for context.<br/><br/>Other compounded telehealth providers range widely, and many charge a separate membership fee on top of medication cost — Ondra does not.</p> </div> <p>The right questions to ask any compounded GLP-1 platform before committing: who is the pharmacy, and can you name them? Is pricing flat across dose levels or does it escalate as you titrate? Is the headline price all-inclusive or does it exclude a required membership fee? Ondra publishes its pharmacy partners publicly and prices are flat and all-inclusive.</p> </div> <div class="ondra-section"> <h2>Channel 2: Manufacturer direct-pay programs (roughly $149–$699/month)</h2> <p>Both Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) have launched subsidized direct-to-consumer programs that offer FDA-approved brand-name products below standard retail prices for cash-pay patients. These are not insurance — they are manufacturer-subsidized cash-pay programs. The figures below are drawn from the manufacturers' published program pages and change over time; verify current pricing directly before relying on any number here.</p> <div class="ondra-info-card"> <p class="ondra-info-title">NovoCare — Wegovy direct-pay (semaglutide)</p> <p>Reported rates have included an oral Wegovy option and injectable Wegovy pen options at various dose tiers, below standard retail. Source: <a href="https://www.novocare.com" target="_blank" rel="noopener noreferrer">novocare.com</a> — check the current published pricing, as these rates change.</p> </div> <div class="ondra-info-card"> <p class="ondra-info-title">LillyDirect — Zepbound direct-pay (tirzepatide)</p> <p>Reported rates have included single-dose Zepbound vials priced by dose tier, below standard retail. Source: <a href="https://lillydirect.lilly.com" target="_blank" rel="noopener noreferrer">lillydirect.lilly.com</a> — check the current published pricing directly.</p> </div> <p>Manufacturer direct-pay products are FDA-approved — they have been reviewed for safety, effectiveness, and manufacturing quality. The clinical trial data (14.9% mean weight loss in STEP 1 for semaglutide; 20.9% mean weight loss at the 15mg dose in SURMOUNT-1 for tirzepatide) applies to these products. For cash-pay patients who specifically want FDA-approved medication and can absorb the premium over compounded, the NovoCare and LillyDirect programs are a legitimate middle path.</p> </div> <div class="ondra-section"> <h2>Channel 3: Retail brand-name without insurance (roughly $900–$1,349/month)</h2> <p>At retail pharmacy pricing without insurance, brand-name GLP-1 medications are expensive enough that relatively few cash-pay patients choose this route given the alternatives above. Wegovy® (semaglutide 2.4mg, Novo Nordisk) lists at approximately $1,349/month at retail. Zepbound® (tirzepatide, Eli Lilly) lists at approximately $1,086/month. Ozempic® and Mounjaro® are in a similar range at retail without insurance. These figures move over time; treat them as approximate and verify before relying on them.</p> <p>These prices reflect brand-name pharmaceutical economics — the cost of FDA approval, multi-phase clinical trials, post-market surveillance, and commercial-scale manufacturing. Most cash-pay patients today access either compounded alternatives or manufacturer direct-pay programs rather than retail pricing.</p> </div> <div class="ondra-section"> <h2>Insurance and GLP-1 coverage</h2> <p>Commercial insurance coverage for GLP-1 medications for chronic weight management remains inconsistent. Coverage for Ozempic and Mounjaro for type 2 diabetes is more established — these have been on formularies longer and have a clearer insurance pathway. Coverage for Wegovy and Zepbound specifically for weight management (not diabetes) is available on some commercial plans but requires prior authorization in most cases and is excluded entirely from many employer-sponsored plans.</p> <div class="ondra-info-card"> <p class="ondra-info-title">How to check your coverage</p> <p>Call the member services number on your insurance card and ask specifically: "Does my plan cover Wegovy (semaglutide) or Zepbound (tirzepatide) for chronic weight management under my current benefits?" Ask about prior authorization requirements, step therapy requirements (being required to try other medications first), and any BMI or comorbidity thresholds. Do not assume coverage based on a general "yes, we cover GLP-1s" — weight management and diabetes indications are often handled differently.</p> </div> <p>If your plan covers brand-name GLP-1 for weight management with a manageable copay, the insurance path is worth pursuing — it gives you the FDA-approved product at potentially lower cost than any compounded alternative. Ondra Health is a cash-pay platform and does not accept insurance; if you have meaningful GLP-1 coverage, explore that path first with your PCP or a platform that works with insurance.</p> </div> <div class="ondra-section"> <h2>Annual cost comparison across channels</h2> <div class="ondra-info-card"> <p class="ondra-info-title">Approximate cost of 12 months of treatment</p> <p><strong>Ondra Health — compounded semaglutide quarterly:</strong> $113 × 12 = about $1,356/year, all-inclusive.<br/><strong>Ondra Health — compounded tirzepatide quarterly:</strong> $183 × 12 = about $2,196/year, all-inclusive.<br/><strong>Manufacturer direct-pay (NovoCare / LillyDirect):</strong> materially higher than compounded, varying by product and dose — see the manufacturers' current pricing.<br/><strong>Retail brand-name without insurance:</strong> roughly $13,000–$16,000/year at approximate list prices.<br/><br/>Ondra's compounded prices are all-inclusive — no membership, no additional fees. Compounded medications are not FDA-approved. Brand-name and direct-pay figures move over time; verify current pricing before relying on any figure here.</p> </div> </div> <div class="ondra-section"> <h2>The regulatory distinction that matters most</h2> <p>The single most important thing to understand when comparing these channels is what FDA approval does and does not mean. FDA-approved products (Wegovy, Zepbound, Ozempic, Mounjaro) have been evaluated by the FDA for safety, effectiveness, and manufacturing quality. The clinical trials that produced the 14.9% and 20.9% weight loss figures were conducted on these specific products at FDA-approved doses.</p> <p>Compounded GLP-1 medications have not been reviewed by the FDA. This does not by itself establish that they are unsafe — compounding pharmacies are subject to state and, for 503B outsourcing facilities, federal oversight. But it does mean the specific safety, efficacy, and quality determinations that come with an FDA-approved product do not apply to compounded versions. Patients choosing compounded GLP-1s are accepting a different regulatory risk profile in exchange for lower cost. That is a legitimate trade-off for many people — it just needs to be understood clearly, and discussed with a licensed provider.</p> </div> <div class="ondra-section"> <h2>Frequently asked questions</h2> <div class="ondra-faq-item"> <h3>What is the cheapest GLP-1 medication?</h3> <p>For cash-pay patients without insurance coverage, compounded semaglutide through a transparent, all-inclusive telehealth platform is typically the lowest-cost option — available from $113/month at Ondra Health on a quarterly plan. Manufacturer direct-pay programs offer FDA-approved products at higher but reduced-from-retail prices. Compounded medications are not FDA-approved and are not therapeutically equivalent to brand-name products. Individual results vary.</p> </div> <div class="ondra-faq-item"> <h3>Is compounded semaglutide as effective as Wegovy?</h3> <p>This has not been established. Compounded semaglutide has not been evaluated in clinical trials of the scale or rigor of the STEP program, so there is no trial evidence comparing it to Wegovy. In principle, the same active molecule at the same dose would be expected to act the same way, but that expectation is not a substitute for testing, and compounded products can vary by pharmacy. Per the FDA, compounded drugs are not FDA-approved and are not therapeutically equivalent to brand-name products. Discuss the trade-offs with your licensed provider.</p> </div> <div class="ondra-faq-item"> <h3>Does Ondra Health accept insurance?</h3> <p>No. Ondra Health is a cash-pay platform. Pricing is transparent and all-inclusive, and does not involve insurance billing, prior authorization, or benefit verification. If you have insurance coverage for GLP-1 weight management medications, it may be worth pursuing that path separately through a platform that works with insurance — Ondra's pricing is designed for patients who either lack GLP-1 coverage or prefer the simplicity of a direct cash-pay model.</p> </div> <div class="ondra-faq-item"> <h3>What is the difference between a 503A and 503B compounding pharmacy?</h3> <p>A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a specific prescription. A 503B pharmacy is a federally registered outsourcing facility subject to FDA oversight that may prepare larger batches, generally under Current Good Manufacturing Practice (cGMP) requirements. Both are recognized compounding pathways. Ondra works with both types depending on the medication and your state. See the <a href="https://ondra.health/blog/503a-vs-503b-compounding-pharmacy">503A vs 503B guide</a> for full detail.</p> </div> </div> <p class="ondra-disclaimer">† This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. Clinical trial data cited: STEP 1 (Wilding et al., <em>NEJM</em>, 2021), 14.9% mean weight loss; SURMOUNT-1 (Jastreboff et al., <em>NEJM</em>, 2022), 20.9% mean weight loss at the 15mg dose — both reflect FDA-approved branded products only. Manufacturer direct-pay and retail pricing figures are approximate, drawn from publicly available program pages, and change over time — verify current pricing before relying on any figure. CDC obesity prevalence data from NHANES 2017–March 2020. Wegovy®, Ozempic® are trademarks of Novo Nordisk. Mounjaro®, Zepbound® are trademarks of Eli Lilly. Ondra Health is not affiliated with either company.</p> </div> <aside class="ondra-article-sidebar" id="ondraSidebarCol"> <div class="ondra-sidebar-track" id="ondraSidebarTrack"> <div class="ondra-sidebar-card-wrap" id="ondraSidebarWrap"> <div class="ondra-sidebar-card" id="ondraSidebarCard"> <div class="ondra-sidebar-top"> <p class="ondra-sidebar-eyebrow">ONDRA HEALTH</p> <h3>Compounded semaglutide from $113/mo — no membership, named pharmacies</h3> </div> <div class="ondra-sidebar-bottom"> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>All-inclusive pricing — no hidden membership</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Named pharmacy partners, publicly listed</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>LegitScript certified, free shipping</p></div> <a href="https://intake.ondra.health/start-online-visit/glp1" class="ondra-sidebar-button">Start your intake <span aria-hidden="true">→</span></a> <p class="ondra-sidebar-note">Only charged if a provider approves your treatment.</p> </div> </div> </div> </div> </aside> </div>
</div>
</section>